| URL | https://www.contractpharma.com/breaking-news/the-n |
| Source | Contract Pharma |
| Date Published | 03/10/2025 |
| Author Name | Charlie Sternberg |
| Company/Division name | Halo Industries |
| Parent company | Noramco |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Capital investment ($): | 25 |
| City reshored to: | Whippany |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma and injectibles |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Eco-system synergies, Impact on domestic economy, Proximity to customers/market, Raw Materials Cost |